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Review Hereditary angioedema: New therapeutic options 
for a potentially deadly disorder
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Abstract
Although the biochemistry of hereditary angioedema (HAE) is fairly well understood today, the lag in diagnosis of a 
decade or more suggests that clinicians have low awareness of this disease. This lag in diagnosis and hence treatment 
certainly stems from the rarity and complexity of the presentation which can be easily mistaken for allergic and non-
allergic reactions alike. The symptoms of the disease include acute swelling of any or multiple parts of the body. The 
attacks may be frequent or rare, and they may vary substantially in severity, causing stomach discomfort or periorbital 
swelling in mild cases and hypovolemic shock due to abdominal fluid shift or asphyxiation in the most severe cases. 
Given that these patients are at significant risk for poor quality of life and death, greater awareness of this disease is 
needed to ensure that newly available, effective medications are used in these patients. These new medications 
represent significant advances in HAE therapy because they are targeted at the plasma cascades implicated in the 
pathophysiology of this disease. The clinical presentation of HAE, overlapping symptoms with other angioedemas, and 
available therapies are reviewed.
Introduction
In 1888, Sir William Osler provided a medical description
of angioedema (AE) that distinguished an inherited form
of the disease[1]. His description was the first to provide
full clinical details. Seventy-five years later, Donaldson
and Evans described patients with clinical features similar
to those first described by Osler. The authors demon-
strated a deficiency of C1 esterase inhibitor in the blood
of these patients, although the extent of the deficiency
was not able to be determined. Today, the biochemistry of
the disease is better understood, but clinicians have low
awareness of hereditary AE (HAE) and other types of
non-allergic AE. Therefore, HAE is frequently undiag-
nosed. Approximately 50% of patients will be symptom-
atic by age 10[2]. However, accurate diagnosis may be
delayed by decades[2]. For many, the disease results in
multiple emergency department visits per year,[3] and for
those patients with abdominal symptoms, one third may
be subjected to inappropriate medical intervention due to
misdiagnosis[4]. The fear of death from asphyxiation is
an unfortunate but common part of life for many patients
with HAE because of the risk of laryngeal swelling.
New medications are available for prophylaxis and
acute treatment of patients with HAE. These new medi-
cations offer targeted actions that reduce the potential for
long-term adverse effects, such as those experienced with
long-term androgen exposure, and they have quick onset
action, making them the best choice for acute treatment.
Increased awareness of HAE symptoms, of available diag-
nostics, and of available treatments among clinicians will
help reduce time to diagnosis and improve disease man-
agement. The following discussion will help clinicians
identify HAE and choose among available therapies.
Mechanism of disease
HAE affects 1:10,000 to 1:50,000 people and is caused by
mutations in the C1 inhibitor gene[5]. The C1 inhibitor
gene is located on chromosome 11, and multiple muta-
tions resulting in C1 inhibitor deficiency have been iden-
tified. Since C1 inhibitor has a broad inhibitory role, C1
inhibitor deficiency affects the regulation of multiple
plasma cascade pathways, namely the contact, fibrin-
olytic, and complement pathways. C1 inhibitor binds
irreversibly in these pathways. Therefore, new C1 inhibi-
tor molecules are needed to maintain homeostasis once
the substrate is bound. However, people with HAE have
C1 inhibitor levels <50% of normal, and they cannot pro-
duce C1 inhibitor fast enough to offset consumption in
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activated pathways[6]. Massive bradykinin release via the
contact pathway is thought to be the primary cause of
symptoms in both HAE and acquired AE[7,8]. Therefore,
the contact pathway has been a target of therapeutic
investigation because C1 inhibitor blocks the activity of
factor XII and kallikrein in this pathway[6]. Since plasma
kallikrein releases bradykinin from high-molecular-
weight kininogen, its inhibition has also been a target of
investigation[6].
Approximately 85% of HAE cases are type 1, a defi-
ciency in the amount of C1 inhibitor produced. Nearly all
other cases are type 2 HAE, which is characterized by the
expression of dysfunctional C1 inhibitor. Inherited C1
inhibitor deficiency with normal C1 inhibitor activity
(formerly HAE type 3) is a very rare disorder seen pri-
marily in women and may be caused by increased activity
of factor XII within the contact pathway, leading to
increased bradykinin and angioedema[2,9]. Although
HAE is primarily an autosomal dominant inherited dis-
ease, it appears de novo in approximately 25% of cases
due to spontaneous mutations.
Presentation and differential diagnosis
Although no clear bias for sex or race has been observed
for HAE, it appears to affect women more severely due to
fluctuating estrogen levels[10]. Evidence for estrogen sen-
sitivity comes from reports of worsening symptoms while
using estrogen-containing oral contraceptives, but not
progesterone-only oral contraceptives[2,11].
Trauma and stress are the most commonly reported
triggers for HAE attacks[12]. In many cases however,
there is no obvious trigger. Swelling episodes due to HAE
typically worsen over one to two days and then resolve
within an additional two days. More severe attacks may
involve 5 days of unremitting symptoms[13]. Any individ-
ual part of the body or multiple sites may be affected[8].
Patients may experience prodromal symptoms that
include tingling or burning in the area of an imminent
attack[9]. Erythema marginatum, a serpiginous, non-pru-
ritic rash may appear on the trunk and appendages as
part of the prodrome in one-third of patients[9]. Inflam-
mation and allergy are not implicated in HAE, and urit-
caria is noteably absent during attacks[14].
More than 90% of patients will experience abdominal
HAE attacks[12]. In most patients, the abdomen will be
protuberant and tender[10]. Bowel sounds will vary
between inactive and hyperactive, and guarding and
rebound tenderness may be present[10]. The pain associ-
ated with abdominal angioedema may have a severe acute
onset or recur as chronic abdominal pain of moderate
severity[6]. Painful abdominal cramps are rated as severe
to excruciating in 87% of patients[15]. In addition, 78% of
patients report vomiting, and 65% report diarrhea with
abdominal pain[15]. Constipation and intestinal obstruc-
tion may also occur[6,12].
Abdominal pain may occur for many years in the
absence of cutaneous symptoms, but this is a rare occur-
rence[16]. HAE abdominal symptoms can be mistaken
for other causes of abdominal pain, such as acute appen-
dicitis[5]. Attacks are frequently accompanied by pro-
dromal symptoms, including nonspecific complaints of
irritability, aggressiveness, fatigue, or hunger[15]. Sub-
stantial fluid accumulation in the intestinal wall and
lumen and in the peritoneal cavity will cause intestinal
wall swelling and ascites. In rare cases, hypovolemic
shock may occur due to the volume of fluid migra-
tion[16]. Patients with abdominal HAE symptoms may
require narcotic analgesics for pain relief, and those at
risk for hypovolemic shock will require aggressive rehy-
dration.
Facial attacks will affect approximately half of all
patients with HAE[6]. Facial attacks may involve severe
swelling, and they carry significant risk of asphyxiation
from extension to the larynx[17]. In the event of laryngeal
involvement, intubation or tracheotomy may be required
to prevent asphyxiation[12].
More than 95% of patients with HAE will experience
extremity attacks[12]. Urogenital attacks are common as
well[8]. Both types of attacks can be triggered by normal
activity and may cause enough discomfort to require
treatment.
In the absence of treatment, a patient with HAE may
experience weekly attacks[9]. Others may have symptom-
free periods of a year or more[18]. Although causes
include physical trauma, surgical/medical/dental proce-
dures, repetitive daily activities, prolonged standing,
infection, emotional stress, and certain medications,
often the cause for an attack cannot be identi-
fied[2,8,10,12].
During an attack, the clinical symptoms of HAE will
include non-pitted, non-pruritic subcutaneous or sub-
mucosal edema, with a possible non-pruritic serpentine
erythematous rash, and may include multiple sites of
swelling[9]. Patients may also experience burning and
pain at the affected site. The extent of C1 inhibitor defi-
ciency is not related to symptom severity or to the bodily
location of an attack[19]. A diagnostic algorithm is pro-
vided to help rule out causative agents and diseases and
to guide laboratory study interpretation (Figure 1).
A thorough patient history and laboratory evaluation
will aid in the differential diagnosis. In 75% of cases, a
thorough patient history will reveal recurrent swelling
episodes without urticaria, a family history of these epi-
sodes, symptom emergence around age 10, and more
severe symptoms starting at puberty[9,10]. Laboratory
markers that will help clinicians distinguish among AEs
appear in Table 1. C4 complement levels are typically lowEidelman BMC Blood Disorders 2010, 10:3
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Figure 1 HAE differential diagnostic algorithm. C4 complement protein levels can be used as a screening test for HAE. Low C1 inhibitor levels sup-
port an HAE diagnosis in the absence of a family history since 25% of HAE cases are the result of spontaneous mutations in individuals. Reproduced 
with permission from Zingale et al.[35]Eidelman BMC Blood Disorders 2010, 10:3
http://www.biomedcentral.com/1471-2326/10/3
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in HAE, whereas C1q and C3 are typically normal[9].
Normal C4 levels during periods of wellness does not
preclude the HAE diagnosis, and repeat values should be
m e a s u r e d  d u r i n g  a n  a c u t e  a t t a c k  w h e n  t h e y  a r e
depressed. Testing for C1 inhibitor antigenic and func-
tional levels provides for a definitive diagnosis and helps
distinguish between HAE types 1 and 2[9].
To further complicate the diagnosis, HAE presentation
may appear to be indistinguishable from idiopathic,
acquired, allergic, or medication-induced AE if the family
history of recurrent swelling is either unknown or absent
– as in the case of spontaneous mutations. In addition,
laboratory studies may prove inconclusive[20]. For exam-
ple, a low/normal C1q level would not help the clinician
distinguish between HAE and acquired angioedema.
Therefore, clinicians may need to include genetic testing
to make a definitive diagnosis. These tests are typically
conducted in research laboratories since commercial lab-
oratories do not yet offer the tests. It is important to note
that not all mutations confer C1 INH deficiency. Clini-
cians can refer to the online database hae.biomem-
brane.hu as the most up-to-date source of documented
mutations for comparison with results for their
patients[21].
Idiopathic AE is the most common type of AE, affecting
one in five people[22]. Idiopathic AE is the presence of ≥
3  s w e l l i n g  e p i s o d e s  i n  s i x  m o n t h s  t o  o n e  y e a r  d e s p i t e
treatment trials[22]. Urticaria and pruritis will be present
in half of cases[22]. Acquired AE is usually caused by a
lymphoproliferative disorder or other autoimmune,
infectious, or neoplastic disease[6]. Acquired AE has
symptoms that closely resemble HAE. However, these
symptoms do not emerge until middle life, helping distin-
guish acquired AE from HAE[23]. Caution should be
exercised when interpreting laboratory studies for C1q
since these levels may be normal in 25% of patients with
acquired angioedema. A normal C1q result does not pre-
clude a diagnosis of acquired angioedema[24,25].
ACE inhibitor use is the second most common cause of
AE and may affect up to 6% of people taking these medi-
cations[26]. People of African descent are approximately
5 times more likely to experience this adverse event than
people of European descent[26]. It typically presents in
the first month of treatment, but may lie dormant for
months or years[26]. The lips, tongue, and face are com-
monly affected sites, but the gastrointestinal tract may be
involved[26]. ACE inhibitor-induced AE has a symptom
p a t t e r n  t h a t  i s  s i m i l a r  t o  H A E .  T h i s  a d v e r s e  e v e n t
emerges when bradykinin degradation is slowed due to
ACE inhibition[26]. The potential for increased availabil-
ity of bradykinin makes this medication inappropriate for
patients with HAE. Discontinuation remains the only
treatment for ACE inhibitor-induced swelling.
In allergic AE, histamine is released via IgE-mediated
mast cell degranulation in response to environmental
allergens. In some patients, degranulation results from
medication or contrast medium exposure. Autoantibody
action involving IgE receptors on mast cells or basophils
is also implicated in allergic AE.
Available therapies
Available therapies are summarized in Table 2.
Acute Treatment
Two acute treatments have recently become available in
the United States. These medications provide an advance
in available acute treatments, particularly because they
are quick acting and directed at targets implicated in the
pathophysiology of HAE. Although C1 INH has been
used for 30 years in Europe and is currently marketed
Table 1: C1 inhibitor levels and complement protein concentrations in angioedemas .
Angioedema Type C1 inhibitor Functional C1 
inhibitor
C4 C3 C1q
HAE type 1 <30% <30% Low Normal Normal
HAE type 2 Normal/High <30% Low Normal Normal
Inherited angioedema with normal C1 
inhibitor
Normal Normal Normal Normal Normal
Acquired Low Low <30% Normal/Low Normal/Low
Angiotensin converting enzyme 
inhibitor induced
Normal Normal Normal Normal Normal
Idiopathic Normal Normal Normal Normal NormalEidelman BMC Blood Disorders 2010, 10:3
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under the name Berinert P®, this plasma-derived C1
esterase inhibitor (human) was recently approved in the
United States for the treatment of acute abdominal or
facial HAE attacks in adults and adolescents. The medi-
cation is marketed under the name Berinert®  in the
United States[27]. In a randomized, double-blind, pla-
cebo-controlled study that enrolled 125 adults and ado-
lescents with HAE, patients were randomized to C1
inhibitor 10 units/kg, C1 inhibitor 20 units/kg, or placebo
intravenous infusion[28]. Patients who received the 20
units/kg dose during an acute abdominal or facial HAE
attack reported significantly shorter time to onset of relief
compared with those receiving 10 units/kg or those
receiving placebo. Berinert® is supplied in 500 unit vials
and administered intravenously at a dosage of 20 units
per kg of body weight. The most common adverse reac-
tions included subsequent HAE attack, abdominal pain,
diarrhea, headache, muscle spasms, nausea, pain, and
vomiting.
The kallikrein inhibitor, KALBITOR®, was also recently
approved in the United States for the treatment of acute
HAE attacks in patients 16 years and older[29]. Kallikrein
inhibitor has not been approved for use by the European
Medicines Agency. KALBITOR® was studied in two dou-
ble-blind, randomized, clinical trials that enrolled 143
individuals. In these trials, patients who were having an
HAE attack at any anatomic location and who were expe-
riencing at least one moderate to severe symptom were
randomized to either 30 mg subcutaneous KALBITOR®
or placebo. Patients who received active medication
reported statistically significant symptom improvement
on a point-in-time symptom severity measure and a
symptom response to treatment measure. More patients
who received placebo required intervention for unre-
solved symptoms (50% vs. 33% of patients). KALBITOR®
is supplied in 10 mg vials. The approved 30 mg dosage is
achieved via three subcutaneous injections, each contain-
ing 10 mg of the medication. Common adverse events
(occurring in ≥ 3% of patients and higher than placebo) in
these trials included headache, nausea, diarrhea, pyrexia,
injection site reactions, and nasopharyngitis. Adverse
event rates were higher when patients who received intra-
venous infusion of KALBITOR® were included in the anal-
ysis. KALBITOR® carries the risk of anaphylaxis. A black
box warning is included in the prescribing information.
Firazyr®, icatibant (bradykinin β2-receptor inhibitor), is
approved in Europe for acute treatment. Icatibant has
been studied in two clinical trials[21,30]. In the random-
ized, double-blind, placebo-controlled FAST-1 trial, no
treatment difference was observed between subcutane-
ous icatibant 30 mg and placebo in median time to symp-
tom relief in adults with moderate to severe abdominal or
cutaneous symptoms, although secondary endpoints
showed benefit from icatibant administration. In the
comparator-controlled, FAST-2 trial, subcutaneous icati-
bant 30 mg was shown to reduce time to onset of symp-
tom relief compared with tranexamic acid in adults with
abdominal or cutaneous symptoms. Subanalyses of these
trials suggest that icatibant may be as effective for laryn-
geal swelling as for abdominal and cutaneous symptoms,
with a time to first symptom improvement of ≤ 1 hour.
Icatibant is supplied in a 30 mg dose and is administered
Table 2: Therapies for various angioedemas .
Angioedema type Therapies*
HAE type 1
HAE type 2
Inherited angioedema with normal C1 
inhibitor
Acute treatment
C1 inhibitor
Kallikrein inhibitor
Bradykinin β2-receptor inhibitor
Prophylaxis
C1 inhibitor
Danazol
Antifibrinolytics are used in clinical 
practice.
There are no approved therapies for 
medical/dental procedure prophylaxis.
Acquired Acute treatment
C1 inhibitor is the treatment of choice for 
laryngeal attacks. Doses greater than 1000 
units may be required.
Prophylaxis
Treatment of underlying disease.
Antifibrinolytics are the first choice for 
long-term therapy, followed by 
attenuated androdgens.
Angiotensin converting enzyme 
inhibitor induced
ACE inhibitor discontinuation.
Idiopathic Antihistamines followed by glucocorticoids.
*See text for United States vs. European approvals.Eidelman BMC Blood Disorders 2010, 10:3
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subcutaneously. Common adverse events include mild
injection-site reactions, abdominal pain, abnormal liver
function tests, asthenia, dizziness, headache, nasal con-
gestion, nausea, rash, and increased blood creatinine
phosphokinase.
Rhucin®, recombinant C1 inhibitor, is currently under
review by the European Medicines Agency for the acute
treatment of HAE attacks.
Prophylaxis
Routine prophylaxis has been shown to reduce the fre-
quency and severity of HAE attacks. Danazol and C1
inhibitor are the only medications approved in the United
States for prophylaxis. In Europe, attenuated androgens,
antifibrinolytics, and C1 INH are used for prophylaxis.
Although guidelines suggest that antifibrinolytics may be
the least effective therapy[5]. The attenuated androgens,
such as danazol, increase C1 inhibitor via the liver and
carry the risk of long-term side effects[31]. An 84%
reduction in the mean number of HAE attacks was asso-
ciated with danazol prophylaxis in a retrospective study
of 118 patients[32]. Nearly one-quarter of patients
reported no HAE symptoms while on danazol therapy.
Other patients continued to have attacks at a reduced fre-
quency. Danazol is supplied in 200 mg, 100 mg, and 50
mg capsules and indicated for use in adults[33]. The 200
mg starting dose may be reduced to 100 mg in patients
who do not experience significant breakthrough symp-
toms[33]. In clinical practice, danazol may be initially
dosed as high as 600 mg/day and then titrated down to
the lowest effective dose[9]. Adverse events were
reported by nearly 80% of patients on danazol therapy
and included weight gain, menstrual irregularities, female
virilization, acne, headache, depression, and myalgia.
Infrequent but serious cardiovascular and other adverse
events were also reported.
The C1 inhibitor CINRYZE™ (C1 esterase inhibitor
[human]) was recently approved in the United States for
routine prophylaxis in adults and adolescents. In a ran-
domized, double-blind, placebo-controlled, cross-over
study, patients on active treatment experienced half as
many HAE attacks as patients who received placebo[34].
Patients who experienced attacks while on C1 inhibitor
therapy reported less severe and shorter attacks com-
pared with those reported by patients on placebo. The
study enrolled 24 patients with a history of ≥ 2 HAE
attacks per month. Patients were randomized to either
treatment arm: 1) 12 weeks of C1 inhibitor therapy, then
12 weeks of placebo or 2) 12 weeks of placebo, then 12
weeks of C1 inhibitor therapy. Twenty-two patients
crossed over and received at least one dose of each study
drug and completed the entire study. CINRYZE™ is
administered intravenously every 3 to 4 days at a dose of
1000 units[34]. Upper respiratory infection, sinusitis,
rash, and headache were the most commonly reported
adverse reactions[34].
Although there are no approved treatments for medical
or dental procedure prophylaxis, consensus guidelines
recommend administration of C1 inhibitor one hour
prior to procedures, with additional doses available at the
time of the procedure, and as necessary thereafter[5]. The
guidelines recommend high-dose danazol and fresh fro-
zen plasma as second-line therapy[9].
Summary
Advances in treatment for HAE have recently come to the
market. These therapies have reduced potential for the
long-term effects associated with attenuated androgen
therapy and the adverse events associated with antifibrin-
olytics, both of which have been mainstays of treatment
in the past. The newly available C1 inhibitor, kallikrein
inhibitor, and bradykinin β2-receptor inhibitor work
directly to reduce the massive bradykinin release in the
contact plasma cascade that is thought to be the primary
pathological mechanism in HAE. Appropriate prophylac-
tic and acute use of these medications will help reduce
patient risk for disability and death. Increased awareness
of this disease and efficient steps in its differential diag-
nosis are essential to improving patient outcomes.
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